Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

By afschroeder • November 4, 2026

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase 2 Trial of ⁸⁹Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma. Radiology. 2026 Nov;321(2):e260517. doi: 10.1148/radiol.260517. PMID: 42975307.

Tags: Hematology/Oncology, Publications

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]

Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

Valentín López JC, Ho A, Hughes KS, Bardia A, Vidula N. Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from[...]

PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in pancreatic cancer

Kim KJ, Lee CH, Nam M, Na HY, Sung JH, Park BR, Hwang SH, Park W, Seo J, Kang M, Jung EH, Kim SA, Suh[...]